{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:56:12Z","timestamp":1790726172559,"version":"4.1.0"},"reference-count":237,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.ejmech.2016.11.025","type":"journal-article","created":{"date-parts":[[2016,11,12]],"date-time":"2016-11-12T23:17:30Z","timestamp":1478992650000},"page":"1300-1320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":108,"special_numbering":"C","title":["Comprehensive review on various strategies for antimalarial drug discovery"],"prefix":"10.1016","volume":"125","author":[{"given":"Mitali","family":"Mishra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikash K.","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Kashaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun K.","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushil Kumar","family":"Kashaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2016.11.025_bib1","unstructured":"World Malaria Report 2015 http:\/\/www.who.int\/malaria\/publications\/world_malaria_report_2015\/report\/en\/."},{"key":"10.1016\/j.ejmech.2016.11.025_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/med.20062","article-title":"Recent advances in antimalarial drug development","volume":"27","author":"Vangapandu","year":"2007","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2016.11.025_bib3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1186\/cc2183","article-title":"Clinical review: severe malaria","volume":"7","author":"Trampuz","year":"2003","journal-title":"Crit. Care"},{"key":"10.1016\/j.ejmech.2016.11.025_bib4","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0169-4758(00)01793-2","article-title":"Molecular approaches to epidemiology and clinical aspects of malaria","volume":"16","author":"Brown","year":"2000","journal-title":"Parasitol. Today"},{"key":"10.1016\/j.ejmech.2016.11.025_bib5","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1128\/AAC.32.6.793","article-title":"Antimalarial agents: mechanisms of action","volume":"32","author":"Schlesinger","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2016.11.025_bib6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/jac\/18.Supplement_B.51","article-title":"Antimalarial drugs: mode of action and resistance","volume":"18","author":"Warhurst","year":"1986","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2016.11.025_bib7","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.3390\/molecules15031705","article-title":"The molecular mechanism of action of artemisinin\u2013the debate continues","volume":"15","author":"O'Neill","year":"2010","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2016.11.025_bib8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1128\/AAC.27.1.21","article-title":"Oxygen- and time-dependent effects of antibiotics and selected mitochondrial inhibitors on Plasmodium falciparum in culture","volume":"27","author":"Divo","year":"1985","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2016.11.025_bib9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4269\/ajtmh.1983.32.221","article-title":"Effects of antibiotics on Plasmodium falciparum in\u00a0vitro","volume":"32","author":"Geary","year":"1983","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ejmech.2016.11.025_bib10","doi-asserted-by":"crossref","first-page":"413","DOI":"10.4269\/ajtmh.2003.68.413","article-title":"Recovery of chloroquine sensitivity and low prevalence of the Plasmodium falciparum chloroquine resistance transporter gene mutation K76T following the discontinuance of chloroquine use in Malawi","volume":"68","author":"Mita","year":"2003","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ejmech.2016.11.025_bib11","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1086\/322858","article-title":"Chloroquine-resistant malaria","volume":"184","author":"Wellems","year":"2001","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ejmech.2016.11.025_bib12","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1128\/AAC.48.6.2116-2123.2004","article-title":"Evolution of resistance to sulfadoxine-pyrimethamine in plasmodium falciparum","volume":"48","author":"Gatton ML","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2016.11.025_bib13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.1365-3156.2003.01167.x","article-title":"The efficacy of chloroquine, sulfadoxine-pyrimethamine and a combination of both for the treatment of uncomplicated Plasmodium falciparum malaria in an area of low transmission in western Uganda","volume":"9","author":"Ndyomugyenyi","year":"2004","journal-title":"Trop. Med. Int. Health"},{"key":"10.1016\/j.ejmech.2016.11.025_bib14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.trstmh.2005.07.017","article-title":"Efficacy of chloroquine, sulfadoxine\u2014pyrimethamine and amodiaquine for treatment of uncomplicated Plasmodium falciparum malaria among children under five in Bongor and Koumra, Chad","volume":"100","author":"Grandessoa","year":"2006","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.ejmech.2016.11.025_bib15","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0140-6736(01)05557-X","article-title":"Amodiaquine, sulfadoxine\/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial","volume":"358","author":"Staedke","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2016.11.025_bib16","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/jac\/dkm337","article-title":"A\u00a0systematic review and meta-analysis of the effectiveness and safety of atovaquone proguanil (Malarone) for chemoprophylaxis against malaria","volume":"60","author":"Nakato","year":"2007","journal-title":"Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2016.11.025_bib17","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2174\/0929867023369691","article-title":"New trends in anti-malarial agents","volume":"15","author":"Frederich","year":"2002","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib18","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1128\/AAC.44.8.2100-2108.2000","article-title":"Mutations in plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site","volume":"44","author":"Korsinczky","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2016.11.025_bib19","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1128\/AAC.46.8.2700-2703.2002","article-title":"Biguanide-atovaquone synergy against plasmodium falciparum in\u00a0vitro","volume":"46","author":"Jones","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2016.11.025_bib20","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2875-7-23","article-title":"In\u00a0vitro atovaquone\/proguanil susceptibility and characterization of the cytochrome b gene of Plasmodium falciparum from different endemic regions of Thailand","volume":"7","author":"Khositnithikul","year":"2008","journal-title":"Mal. J."},{"key":"10.1016\/j.ejmech.2016.11.025_bib21","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1590\/S0037-86822004000300015","article-title":"Efficacy of sulfadoxine-pyrimethamine and mefloquine for the treatment of uncomplicated Plasmodium falciparum malaria in the Amazon basin of Peru","volume":"37","author":"Magill","year":"2004","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"10.1016\/j.ejmech.2016.11.025_bib22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0035-9203(93)90431-O","article-title":"Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life","volume":"87","author":"Watkins","year":"1993","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.ejmech.2016.11.025_bib23","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1128\/AAC.00241-08","article-title":"Plasmodium falciparum pfmdr1 amplification, mefloquine resistance, and parasite fitness","volume":"53","author":"Preechapornkul","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2016.11.025_bib24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0169-4758(97)01003-X","article-title":"Why does quinine still work after 350 years of use?","volume":"13","author":"Meshnick","year":"1997","journal-title":"Parasitol. Today"},{"key":"10.1016\/j.ejmech.2016.11.025_bib25","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/1475-2875-10-144","article-title":"Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria","volume":"10","author":"Achan","year":"2011","journal-title":"Malar. J."},{"key":"10.1016\/j.ejmech.2016.11.025_bib26","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1136\/bmj.332.7549.1055","article-title":"Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria","volume":"332","author":"Barennes","year":"2006","journal-title":"Brit. Med. J."},{"key":"10.1016\/j.ejmech.2016.11.025_bib27","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1046\/j.1365-2125.1996.03246.x","article-title":"Efficacy and pharmacokinetics of a new intrarectal quinine formulation in children with Plasmodium falciparum malaria","volume":"41","author":"Barennes","year":"1996","journal-title":"Brit. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2016.11.025_bib28","first-page":"121","article-title":"Failures following initial treatment for uncomplicated malaria: quinine as second line therapy","volume":"2","author":"Kofoed","year":"2007","journal-title":"J.\u00a0Pediatr. Infect. Dis."},{"key":"10.1016\/j.ejmech.2016.11.025_bib29","first-page":"15","article-title":"Quinine-tetracycline for multidrug resistant falciparum malaria","volume":"27","author":"Bunnag","year":"1996","journal-title":"Southeast Asian J. Trop. Med. Public Health"},{"key":"10.1016\/j.ejmech.2016.11.025_bib30","first-page":"502","article-title":"Treatment of uncomplicated Plasmodium falciparum malaria with quinine-doxycycline combination therapy","volume":"57","author":"Ejaz","year":"2007","journal-title":"J.\u00a0Pak. Med. Assoc."},{"key":"10.1016\/j.ejmech.2016.11.025_bib31","doi-asserted-by":"crossref","first-page":"401","DOI":"10.4269\/ajtmh.2006.74.401","article-title":"Effective treatment of uncomplicated Plasmodium falciparum malaria with azithromycin-quinine combinations: a randomized, dose-ranging study","volume":"74","author":"Miller","year":"2006","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ejmech.2016.11.025_bib32","doi-asserted-by":"crossref","first-page":"517","DOI":"10.4269\/ajtmh.2011.10-0285","article-title":"Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis","volume":"84","author":"Tan","year":"2011","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ejmech.2016.11.025_bib33","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/jac\/47.1.43","article-title":"Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study","volume":"47","author":"Wistr\u00f6m","year":"2001","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2016.11.025_bib34","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1128\/AAC.46.8.2315-2320.2002","article-title":"Clindamycin as an antimalarial drug: review of clinical trials","volume":"46","author":"Lell","year":"2002","journal-title":"Antimicrob. Agent Chemother."},{"key":"10.1016\/j.ejmech.2016.11.025_bib35","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1475-2875-11-2","article-title":"Clindamycin plus quinine for treating uncomplicated falciparum malaria: a systematic review and meta-analysis","volume":"11","author":"Obonyo","year":"2012","journal-title":"Malar. J."},{"key":"10.1016\/j.ejmech.2016.11.025_bib36","series-title":"Defining and Defeating the Intolerable Burden of Malaria III: Progress and Perspectives: Supplement to Volume 77(6) of American Journal of Tropical Medicine and Hygiene","article-title":"Artemisinin-based combination treatment of falciparum malaria","author":"Nosten","year":"2007"},{"key":"10.1016\/j.ejmech.2016.11.025_bib37","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1475-2875-6-80","article-title":"Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal","volume":"6","author":"Faye","year":"2007","journal-title":"Malar. J."},{"key":"10.1016\/j.ejmech.2016.11.025_bib38","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1128\/AAC.01466-13","article-title":"Evidence for pyronaridine as a highly effective partner drug for treatment of artemisinin-resistant malaria in a rodent model","volume":"58","author":"Henrich","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2016.11.025_bib39","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1473-3099(15)00318-7","article-title":"Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial","volume":"16","author":"Sagara","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejmech.2016.11.025_bib40","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2165\/11203910-000000000-00000","article-title":"Dihydroartemisinin\/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malaria","volume":"72","author":"Keating","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2016.11.025_bib41","doi-asserted-by":"crossref","first-page":"466","DOI":"10.4103\/2141-9248.139270","article-title":"Fixed dose combination of Arterolane and piperaquine: a newer prospect in antimalarial therapy ann","volume":"4","author":"Patil","year":"2014","journal-title":"Med. Health Sci. Res."},{"key":"10.1016\/j.ejmech.2016.11.025_bib42","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/cid\/cis475","article-title":"Arterolane maleate plus piperaquine phosphate for treatment of uncomplicated Plasmodium falciparum malaria: a comparative, multicenter, randomized clinical trial","volume":"55","author":"Valecha","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2016.11.025_bib43","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.3390\/ph3123581","article-title":"Artemisinin-Naphthoquine combination (ARCO\u00ae): an overview of the progress","volume":"3","author":"Hombhanje","year":"2010","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2016.11.025_bib44","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1128\/AAC.06248-11","article-title":"Artemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria: a tolerability, safety, and preliminary efficacy study","volume":"56","author":"Benjamin","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2016.11.025_bib45","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1074\/jbc.M608615200","article-title":"In\u00a0vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin","volume":"282","author":"Sidhu","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib46","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1517\/17425255.2011.598506","article-title":"Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually transmitted infections in pregnancy","volume":"7","author":"Chico","year":"2011","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejmech.2016.11.025_bib47","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02198807."},{"key":"10.1016\/j.ejmech.2016.11.025_bib48","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1473-3099(15)00079-1","article-title":"Ferroquine and artesunate in African adults and children with Plasmodium falciparum malaria: a phase 2, multicentre, randomised, double-blind, dose-ranging, non-inferiority study","volume":"15","author":"Held","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejmech.2016.11.025_bib49","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01361269."},{"key":"10.1016\/j.ejmech.2016.11.025_bib50","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(13)62568-4","article-title":"Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria: a multicentre, double-blind, randomised, phase 2b dose-selection study","volume":"383","author":"Llanos-Cuentas","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2016.11.025_bib51","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2875-10-212","article-title":"Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta)","volume":"10","author":"Dow","year":"2011","journal-title":"Malar. J."},{"key":"10.1016\/j.ejmech.2016.11.025_bib52","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02297477."},{"key":"10.1016\/j.ejmech.2016.11.025_bib53","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1473-3099(03)00547-4","article-title":"The development of Lapdap, an affordable new treatment for malaria","volume":"3","author":"Lang","year":"2003","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejmech.2016.11.025_bib54","unstructured":"https:\/\/clinicaltrials.gov\/show\/NCT00371735."},{"key":"10.1016\/j.ejmech.2016.11.025_bib55","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2875-12-263","article-title":"Identification of resistance of Plasmodium falciparum to artesunate-mefloquine combination in an area along the Thai-Myanmar border: integration of clinico-parasitological response, systemic drug exposure, and in\u00a0vitro parasite sensitivity","volume":"12","author":"Na-Bangchang","year":"2013","journal-title":"Malar. J."},{"key":"10.1016\/j.ejmech.2016.11.025_bib56","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3347\/kjp.2008.46.2.65","article-title":"Gametocyte clearance in uncomplicated and severe Plasmodium falciparum malaria after artesunate-mefloquine treatment in Thailand","volume":"46","author":"Tangpukdee","year":"2008","journal-title":"Korean J. Parasitol."},{"key":"10.1016\/j.ejmech.2016.11.025_bib57","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1086\/498249","article-title":"Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease","volume":"192","author":"Thera","year":"2005","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ejmech.2016.11.025_bib58","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1086\/322858","article-title":"Chloroquine-resistant malaria","volume":"184","author":"Wellems","year":"2001","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ejmech.2016.11.025_bib59","first-page":"45","article-title":"Drug resistance in malaria","volume":"41","author":"Farooq","year":"2004","journal-title":"J.\u00a0Vect. Bor. Dis."},{"key":"10.1016\/j.ejmech.2016.11.025_bib60","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4269\/ajtmh.1996.55.579","article-title":"Aminoquinolines that circumvent resistance in Plasmodium falciparum in\u00a0vitro","volume":"55","author":"De","year":"1996","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ejmech.2016.11.025_bib61","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1128\/AAC.40.8.1846","article-title":"4-aminoquinoline analogs of chloroquine with shortened side chains retain activity against chloroquine-resistant Plasmodium falciparum","volume":"40","author":"Ridley","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2016.11.025_bib62","unstructured":"D. Krogstad, Clinical trials. gov Identifier:NCT01614964( 2015)."},{"key":"10.1016\/j.ejmech.2016.11.025_bib63","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.4269\/ajtmh.2006.75.1178","article-title":"In\u00a0vitro activity of ferroquine (SAR97193) is independent 52of chloroquine resistance in plasmodium falciparum","volume":"75","author":"Kreidenweiss","year":"2006","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ejmech.2016.11.025_bib64","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1128\/AAC.01572-09","article-title":"Plasmodium vivax susceptibility to ferroquine","volume":"54","author":"Leimanis","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2016.11.025_bib65","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1021\/ml300062q","article-title":"Deciphering the resistance-counteracting functions of ferroquine in plasmodium falciparum-infected erythrocytes","volume":"3","author":"Dubar","year":"2012","journal-title":"ACS. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.11.025_bib66","doi-asserted-by":"crossref","first-page":"7690","DOI":"10.1002\/anie.201303690","article-title":"The ferroquine antimalarial conundrum: redox activation and reinvasion inhibition","volume":"52","author":"Dubar","year":"2013","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2016.11.025_bib67","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/bmj.292.6522.721","article-title":"Amodiaquine induced Agranulocytes and liver damage","volume":"292","author":"Nheftel","year":"1986","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ejmech.2016.11.025_bib68","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1136\/bmj.1.5851.458","article-title":"Amodiaquine induced agranulocytosis; Toxic effects of amodiaquine in Bone marrow culture in\u00a0vitro","volume":"1","author":"Lind","year":"1973","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ejmech.2016.11.025_bib69","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0006-2952(88)90733-2","article-title":"Drug protein conjugates-XIN. Mechanism of formation of protein arylating intermediates from amodiaquine a myelotoxin and hepatotoxin in man","volume":"37","author":"Maggs","year":"1988","journal-title":"Biochem. Pharm."},{"key":"10.1016\/j.ejmech.2016.11.025_bib70","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1021\/jm8012618","article-title":"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century","volume":"52","author":"O'neill","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib71","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1021\/jm8012757","article-title":"Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4\u2032-fluoro and 4\u2032-chloro analogues of amodiaquine. Identification of a suitable \u201cback-up\u201d compound for N-tert-butyl isoquine","volume":"52","author":"O'neill","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib72","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1021\/op7002776","article-title":"Development of a scalable synthetic route to GSK369796 (N-tert-butyl isoquine), a novel 4-Aminoquinoline antimalarial drug","volume":"12","author":"Lawrence","year":"2008","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejmech.2016.11.025_bib73","first-page":"1","article-title":"Tafenoquine for preventing relapse in people with Plasmodium vivax malaria","volume":"29","author":"Rajapakse","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejmech.2016.11.025_bib74","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/bdd.547","article-title":"In\u00a0Vitro and in\u00a0Vivo pharmacokinetic studies of bulaquine (analogue of primaquine), a novel antirelapse antimalarial, in rat, rabbit and monkey-highlighting species similarities and differences","volume":"28","author":"Mehrotra","year":"2007","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejmech.2016.11.025_bib75","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2165\/00003495-200565010-00004","article-title":"Piperaquine: a resurgent antimalarial drug","volume":"65","author":"Davis","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2016.11.025_bib76","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1021\/jm00089a025","article-title":"Bisquinolines. 1. N,N-bis(7-chloroquinolin-4-yl)alkanediamines with potential against chloroquine-resistant malaria","volume":"35","author":"Vennerstrom","year":"1992","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib77","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0020-7519(98)00217-3","article-title":"Bisquinoline antimalarials: their role in malaria chemotherapy","volume":"29","author":"Raynes","year":"1999","journal-title":"Inter. J. Parasitol."},{"key":"10.1016\/j.ejmech.2016.11.025_bib78","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1128\/AAC.41.3.677","article-title":"Antimalarial activity of the bisquinoline trans-N1 ,N2 \u2013bis (7-Chloroquinolin-4- yl)cyclohexane-1,2-diamine: comparison of two stereoisomers and detailed evaluation of the S, S enantiomer, Ro 47-7737","volume":"41","author":"ridley","year":"1997","journal-title":"Antimicrob. agents Chemother."},{"key":"10.1016\/j.ejmech.2016.11.025_bib79","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.2042-7158.1998.tb06189.x","article-title":"Novel Aryl-bis-quinolines with Antimalarial Activity In-vivo","volume":"50","author":"Ismail","year":"1998","journal-title":"J.\u00a0Pharm. Pharmocol."},{"key":"10.1016\/j.ejmech.2016.11.025_bib80","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1021\/jm001096a","article-title":"Antiplasmodial activity and cytotoxicity of bis-, Tris-, and Tetraquinolines with linear or cyclic amino linkers","volume":"44","author":"Girault","year":"2001","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib81","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ejmech.2012.07.037","article-title":"Synthesis and in\u00a0vitro antimalarial activity of a series of bisquinoline and bispyrrolo[1,2a]quinoxaline compounds","volume":"55","author":"Heerdena","year":"2012","journal-title":"Eu. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib82","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1021\/ar7000843","article-title":"Hybrid molecules with a dual mode of action: dream or reality","volume":"41","author":"Meunier","year":"2008","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejmech.2016.11.025_bib83","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/ddr.20345","article-title":"Next-generation antimalarial drugs: hybrid molecules as a new strategy in drug design","volume":"71","author":"Muregi","year":"2010","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.ejmech.2016.11.025_bib84","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1590\/S0074-02762012000700001","article-title":"New approaches in antimalarial drug discovery and development - a Review","volume":"107","author":"Aguiar","year":"2012","journal-title":"Mem. Inst."},{"key":"10.1016\/j.ejmech.2016.11.025_bib85","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/1439-7633(20001117)1:4<281::AID-CBIC281>3.0.CO;2-W","article-title":"Preparation and antimalarial activities of \u201ctrioxaquines,\u201d new modular molecules with a trioxane skeleton linked to a 4-aminoquinoline","volume":"1","author":"Dechy-Cabaret","year":"2000","journal-title":"Chem. Biol. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib86","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/chem.200305576","article-title":"Synthesis and antimalarial activity of trioxaquine derivatives","volume":"10","author":"Dechy-Cabaret","year":"2004","journal-title":"Chem. Eur. J."},{"key":"10.1016\/j.ejmech.2016.11.025_bib87","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1128\/AAC.00967-06","article-title":"Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes","volume":"51","author":"Benoit-Vical","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2016.11.025_bib88","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1128\/AAC.00165-08","article-title":"The antimalarial trioxaquine DU1301 alkylates heme in malaria-infected mice","volume":"52","author":"Bousejra-EI Garah","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2016.11.025_bib89","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/cbic.200400249","article-title":"Heme alkylation by the antimalarial endoperoxides artesunate and trioxaquine","volume":"6","author":"Laurent","year":"2005","journal-title":"Chem. Biol. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib90","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0010-8545(99)00112-5","article-title":"The role of haem in the activity of chloroquine and related antimalarial drugs","volume":"190","author":"Egan","year":"1999","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.ejmech.2016.11.025_bib91","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1128\/AAC.00239-07","article-title":"Trioxaquines and heme-artemisinin adducts inhibit the in\u00a0vitro formation of hemozoin better than chloroquine","volume":"51","author":"Loup","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2016.11.025_bib92","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1128\/AAC.00967-06","article-title":"Trioxaquines: new antimalarial agents active on all erythrocytic forms including gametocytes","volume":"51","author":"Benoit-Vical","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2016.11.025_bib93","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.bmcl.2009.10.106","article-title":"Synthesis, antimalarial activity and cytotoxicity of 4-aminoquinoline\u2013triazine conjugates","volume":"20","author":"Manohar","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.11.025_bib94","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1747-0285.2011.01115.x","article-title":"Synthesis of 4-aminoquinoline-1,2,3-triazole and 4-aminoquinoline- 1,2,3-triazole-1,3,5-triazine hybrids as potential antimalarial agents","volume":"78","author":"Manohar","year":"2011","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2016.11.025_bib95","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/cbdd.12108","article-title":"4-Aminoquinoline-triazine-based hybrids with improved in\u00a0vitro antimalarial activity against CQ-sensitive and CQ-resistant strains of plasmodium falciparum","volume":"81","author":"Manohar","year":"2013","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2016.11.025_bib96","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1021\/ml3000808","article-title":"Novel 4-aminoquinoline-pyrimidine based hybrids with improved in\u00a0vitro and in\u00a0vivo antimalarial activity","volume":"3","author":"Manohar","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.11.025_bib97","first-page":"3249","article-title":"Synthesis, characterization and antimalarial activity of quinoline\u2212pyrimidine hybrids","volume":"13","author":"Pretorius","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib98","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ejmech.2013.05.046","article-title":"Synthesis of 4-aminoquinoline\u2212pyrimidine hybrids as potent antimalarials and their mode of action studies","volume":"66","author":"Singh","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib99","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1021\/jm4014778","article-title":"Quinoline-pyrimidine hybrids: synthesis, antiplasmodial activity, SAR, and mode of action studies","volume":"57","author":"Singh","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib100","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1021\/jm301422h","article-title":"Structural characteristics of chloroquine-bridged ferrocenophane analogues of ferroquine may obviate malaria drug resistance mechanisms","volume":"56","author":"Salas","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib101","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/cmdc.200700127","article-title":"Ferrocene conjugates of chloroquine and other antimalarials: the development of ferroquine, a new antimalarial","volume":"3","author":"Dive","year":"2008","journal-title":"Chem. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib102","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ejmech.2013.01.017","article-title":"Synthesis and biological evaluation of a new class of 4-aminoquinoline-rhodanine hybrid as potent anti-infective agents","volume":"62","author":"Chauhan","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib103","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1016\/j.bmc.2005.02.037","article-title":"Design, synthesis and anti-plasmodial evaluation in\u00a0vitro of new 4-aminoquinoline isatin derivatives","volume":"13","author":"Chiyanzu","year":"2005","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib104","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1039\/c2md20238g","article-title":"A\u00a0furoxan\u2212amodiaquine hybrid as a potential therapeutic for three parasitic diseases","volume":"3","author":"Mott","year":"2012","journal-title":"Med. Chem. Comm."},{"key":"10.1016\/j.ejmech.2016.11.025_bib105","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1021\/ml4001084","article-title":"Synthesis, antiplasmodial activity, and \u03b2-hematin inhibition of hydroxypyridone\u2212chloroquine hybrids","volume":"4","author":"Andayi","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.11.025_bib106","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/cbdd.12335","article-title":"Synthesis and evaluation of antimalarial properties of novel 4-Aminoquinoline hybrid compounds","volume":"84","author":"Fisher","year":"2014","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2016.11.025_bib107","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ejmech.2013.08.037","article-title":"Squaric acid\/4-aminoquinoline conjugates: novel potent antiplasmodial agents","volume":"69","author":"Ribeiro","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib108","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ejmech.2015.03.045","article-title":"Synthesis and in\u00a0vitro antiplasmodial evaluation of 7-chloroquinoline-chalcone and 7- chloroquinoline-ferrocenylchalcone conjugates","volume":"95","author":"Raj","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib109","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1128\/AAC.00510-08","article-title":"Synthesis, antimalarial activity, and intracellular targets of MEFAS, a new hybrid compound derived from mefloquine and artesunate","volume":"52","author":"Varotti","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2016.11.025_bib110","series-title":"Transmission Blocking Potential of MEFAS, a Hybrid Compound derived from Artesunate and Mefloquine","author":"Penna-Coutinho","year":"2016"},{"key":"10.1016\/j.ejmech.2016.11.025_bib111","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1039\/c3md00019b","article-title":"Synthesis and biological evaluation of primaquine\u2212chloroquine twin drug: a novel heme-interacting molecule prevents free heme and hydroxyl radical-mediated protein degradation","volume":"4","author":"Pal","year":"2013","journal-title":"Med. Chem. Comm."},{"key":"10.1016\/j.ejmech.2016.11.025_bib112","first-page":"23","article-title":"Design and synthesis of novel hybrid molecules against malaria","volume":"2015","author":"L\u00f6dige","year":"2015","journal-title":"Int. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib113","doi-asserted-by":"crossref","first-page":"369","DOI":"10.6026\/97320630008369","article-title":"Molecular modeling and evaluation of binding mode and affinity of artemisinin-quinine hybrid and its congeners with Fe-protoporphyrin-IX as a putative receptor","volume":"8","author":"Mahapatra","year":"2012","journal-title":"Bioinformation"},{"key":"10.1016\/j.ejmech.2016.11.025_bib114","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.5b01485","article-title":"Antimalarial chemotherapy: natural product inspired development of preclinical and clinical candidates with diverse mechanisms of action","author":"Fern\u00e1ndez-\u00c1lvaro","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib115","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/1475-2875-10-144","article-title":"Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria","volume":"10","author":"Achan","year":"2011","journal-title":"Malar. J."},{"key":"10.1016\/j.ejmech.2016.11.025_bib116","series-title":"Guidelines for the Treatment of Malaria","year":"2010"},{"key":"10.1016\/j.ejmech.2016.11.025_bib117","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/0140-6736(93)90362-K","article-title":"Qinghaosu","volume":"341","author":"Hein","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2016.11.025_bib118","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1126\/science.3887571","article-title":"Qinghaosu (artemisinin): an antimalarial drug from China","volume":"228","author":"Klayman","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2016.11.025_bib119","first-page":"191","article-title":"Discovery of artemisinin: the Chinese wonder drug, Muller J","volume":"5","author":"Udaykumar","year":"2014","journal-title":"Med. Sci. Res."},{"key":"10.1016\/j.ejmech.2016.11.025_bib120","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.toxlet.2003.12.009","article-title":"Artemisinin derivatives: toxic for laboratory animals, safe for humans?","volume":"147","author":"Gordi","year":"2004","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.ejmech.2016.11.025_bib121","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0009-9236(98)90044-3","article-title":"Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria","volume":"63","author":"Ashton","year":"1998","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2016.11.025_bib122","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2174\/157488507781695649","article-title":"Pharmacokinetic and pharmacodynamic profiles of rapid-acting artemisinins in the antimalarial therapy","volume":"2","author":"Li","year":"2007","journal-title":"Curr. Drug Ther."},{"key":"10.1016\/j.ejmech.2016.11.025_bib123","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1021\/jm030571c","article-title":"A\u00a0medicinal chemistry perspective on artemisinin and related endoperoxides","volume":"47","author":"O'Neill","year":"2004","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib124","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1039\/B816679J","article-title":"Artemisinin and its derivatives: a novel class of anti-malarial and anti-cancer agents","volume":"39","author":"Chaturvedi","year":"2010","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2016.11.025_bib125","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2165\/00003088-200039040-00002","article-title":"Pharmacokinetics of artemisinin-type compounds","volume":"39","author":"Navaratnam","year":"2000","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2016.11.025_bib126","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1002\/anie.200503071","article-title":"Artemisone-a highly active antimalarial drug of the artemisinin class","volume":"45","author":"Haynes","year":"2006","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2016.11.025_bib127","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1128\/AAC.01585-07","article-title":"First assessment in humans of the safety, tolerability, pharmacokinetics, and ex\u00a0vivo pharmacodynamic antimalarial activity of the new artemisinin derivative artemisone","volume":"52","author":"Nagelschmitz","year":"2008","journal-title":"Antimicrob. Agents. Chemother."},{"key":"10.1016\/j.ejmech.2016.11.025_bib128","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1128\/AAC.01064-06","article-title":"Mechanism of antimalarial action of the synthetic trioxolane RBX11160 (OZ277)","volume":"51","author":"Uhlemann","year":"2007","journal-title":"Antimicrob. Agents. Chemother."},{"key":"10.1016\/j.ejmech.2016.11.025_bib129","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1021\/jm400004u","article-title":"Comparative antimalarial activities and ADME profiles of ozonides (1,2,4-trioxolanes) OZ277, OZ439, and their 1,2-dioxolane, 1,2,4-trioxane, and 1,2,4,5-tetraoxane isosteres","volume":"56","author":"Wang","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib130","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/clpt.2009.51","article-title":"The global portfolio of new antimalarial medicines under development","volume":"85","author":"Olliaro","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2016.11.025_bib131","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1073\/pnas.1015762108","article-title":"Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria","volume":"108","author":"Charman","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2016.11.025_bib132","first-page":"10","article-title":"Febrifugine analogues: promising antimalarial agents","volume":"1","author":"Mishra","year":"2015","journal-title":"Asian J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejmech.2016.11.025_bib133","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1128\/AAC.49.3.1169-1176.2005","article-title":"Antimalarial activities and therapeutic properties of febrifugine analogs","volume":"49","author":"Jiang","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2016.11.025_bib134","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/j.bmcl.2006.01.009","article-title":"Synthesis and evaluation of febrifugine analogues as potential antimalarial agents","volume":"16","author":"Zhu","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.11.025_bib135","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1016\/j.ejmech.2010.05.040","article-title":"Synthesis and evaluation of 4-quinazolinone compounds as potential antimalarial agents","volume":"45","author":"Zhu","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib136","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.bmc.2011.11.053","article-title":"Febrifugine analogue compounds: synthesis and antimalarial evaluation","volume":"20","author":"Zhu","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib137","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3998\/ark.5550190.0008.204","article-title":"Lapachol: an overview","volume":"2","author":"Hussain","year":"2007","journal-title":"Arkivoc"},{"key":"10.1016\/j.ejmech.2016.11.025_bib138","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejmech.2012.10.052","article-title":"Addition of thiols to o-quinone methide: new 2-hydroxy-3-phenylsulfanylmethyl[1,4]naphthoquinones and their activity against the human malaria parasite Plasmodium falciparum (3D7)","volume":"59","author":"Sharma","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib139","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/1475-2875-12-234","article-title":"Biological evaluation of hydroxynaphthoquinones as antimalarials","volume":"12","author":"Schuck","year":"2013","journal-title":"Malar. J."},{"key":"10.1016\/j.ejmech.2016.11.025_bib140","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ejmech.2013.10.011","article-title":"Synthesis and biological evaluation of novel ferrocene-naphthoquinones as antiplasmodial agents","volume":"70","author":"Garc\u00eda-Barrantes","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib141","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005029","article-title":"Quinolone-3-diarylethers: a new class of antimalarial drug","volume":"5","author":"Nilsen","year":"2013","journal-title":"Sci. Trans. Med."},{"key":"10.1016\/j.ejmech.2016.11.025_bib142","doi-asserted-by":"crossref","first-page":"8298","DOI":"10.1073\/pnas.1205651109","article-title":"Generation of quinolone antimalarials targeting the Plasmodium falciparum mitochondrial respiratory chain for the treatment and prophylaxis of malaria","volume":"109","author":"Biagini","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2016.11.025_bib143","doi-asserted-by":"crossref","first-page":"10131","DOI":"10.3390\/molecules170910131","article-title":"Thomas H. Keller, mechanistic study of the spiroindolones: a new class of antimalarials","volume":"17","author":"Zou","year":"2012","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2016.11.025_bib144","doi-asserted-by":"crossref","first-page":"227","DOI":"10.4155\/fmc.15.177","article-title":"Spiroindolone NITD609 is a novel antimalarial drug that targets the P-type ATPase PfATP4","volume":"8","author":"Turner","year":"2016","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib145","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJM199305273282103","article-title":"Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS","volume":"328","author":"Hughes","year":"1993","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2016.11.025_bib146","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/jac\/dks504","article-title":"Antimalarial pharmacology and therapeutics of atovaquone","volume":"68","author":"Nixon","year":"2013","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2016.11.025_bib147","doi-asserted-by":"crossref","first-page":"5073","DOI":"10.1128\/AAC.05130-11","article-title":"In\u00a0Vitro activity of antiretroviral drugs against plasmodium falciparum","volume":"55","author":"Nsanzabana","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2016.11.025_bib148","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa1200501","article-title":"Antiretroviral agents and prevention of malaria in HIV-Infected Ugandan children","volume":"367","author":"Achan","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2016.11.025_bib149","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1128\/AAC.00022-06","article-title":"Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin","volume":"50","author":"Parikh","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2016.11.025_bib150","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1017\/S0031182013000747","article-title":"Progressing the global antimalarial portfolio: finding drugs which target multiple Plasmodium life stages","volume":"141","author":"Smith","year":"2014","journal-title":"Parasitology"},{"key":"10.1016\/j.ejmech.2016.11.025_bib151","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/jac\/dkl104","article-title":"The past, present and future of antifolates in the treatment of Plasmodium falciparum infection","volume":"57","author":"Nzila","year":"2006","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2016.11.025_bib152","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1126\/science.1211936","article-title":"Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery","volume":"334","author":"Meister","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2016.11.025_bib153","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1128\/AAC.04642-14","article-title":"Antimalarial iron chelator FBS0701 blocks transmission by plasmodium falciparum gametocyte activation inhibition","volume":"59","author":"Ferrer","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2016.11.025_bib154","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1186\/s12936-015-0910-1","article-title":"Inhibitory effect of novel iron chelator, 1-(N-acetyl-6-aminohexyl)-3-hydroxy-2-methylpyridin-4-one (CM1) and green tea extract on growth of Plasmodium falciparum","volume":"14","author":"Thipubon","year":"2015","journal-title":"Malar. J."},{"key":"10.1016\/j.ejmech.2016.11.025_bib155","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.bmcl.2015.03.077","article-title":"Synthesis and antimalarial evaluation of prodrugs of novel fosmidomycin analogues","volume":"25","author":"Phillipsa","year":"2015","journal-title":"Biol. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.11.025_bib156","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1128\/AAC.46.9.2889-2894.2002","article-title":"In\u00a0vitro and in\u00a0vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin","volume":"46","author":"Wiesner","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2016.11.025_bib157","unstructured":"ClinicalTrials.gov identifier: NCT02198807 evaluation of fosmidomycin and piperaquine in the treatment of acute falciparum malaria (FOSPIP), Jomaa Pharm. GmbH, 2015."},{"key":"10.1016\/j.ejmech.2016.11.025_bib158","doi-asserted-by":"crossref","first-page":"12560","DOI":"10.1073\/pnas.0705313104","article-title":"Aquaporin 9 is the major pathway for glycerol uptake by mouse erythrocytes, with implications for malarial virulence","volume":"104","author":"Liu","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2016.11.025_bib159","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrd4226","article-title":"Aquaporins: important but elusive drug targets","volume":"13","author":"Verkman","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2016.11.025_bib160","doi-asserted-by":"crossref","first-page":"e37435","DOI":"10.1371\/journal.pone.0037435","article-title":"Targeting aquaporin function: potent inhibition of Aquaglyceroporin-3 by a gold-based compound","volume":"7","author":"Martins","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2016.11.025_bib161","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.actatropica.2003.11.003","article-title":"The hexose transporter of plasmodium falciparum is a worthy drug target","volume":"89","author":"Joet","year":"2004","journal-title":"Acta Trop."},{"key":"10.1016\/j.ejmech.2016.11.025_bib162","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.bmcl.2005.11.068","article-title":"Probing structure\/affinity relationships for the Plasmodium falciparum hexose transporter with glucose derivatives","volume":"16","author":"Fayolle","year":"2006","journal-title":"Biol. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.11.025_bib163","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/1475-2875-10-165","article-title":"Plasmodial sugar transporters as anti-malarial drug targets and comparisons with other protozoa","volume":"10","author":"Slavic","year":"2011","journal-title":"Malar. J."},{"key":"10.1016\/j.ejmech.2016.11.025_bib164","doi-asserted-by":"crossref","first-page":"36841","DOI":"10.1074\/jbc.M507727200","article-title":"A\u00a0malaria parasite-encoded vacuolar H+-ATPase is targeted to the host erythrocyte","volume":"280","author":"Marchesini","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib165","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.bcp.2009.12.025","article-title":"Inhibition of Plasmodium falciparum pH regulation by small molecule indole derivatives results in rapid parasite death","volume":"79","author":"Van Schalkwyk","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2016.11.025_bib166","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3934\/biophy.2016.1.171","article-title":"Integral membrane pyrophosphatases: a novel drug target for human pathogens?","volume":"3","author":"Shah","year":"2016","journal-title":"AIMS Biophys."},{"key":"10.1016\/j.ejmech.2016.11.025_bib167","first-page":"3454","article-title":"Choline analogues in malaria chemotherapy","volume":"18","author":"Peyrottes","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejmech.2016.11.025_bib168","first-page":"259","article-title":"Effect of choline kinase inhibitor hexadecyltrimethylammonium bromide on plasmodium falciparum gene expression","volume":"45","author":"Ridzuan","year":"2014","journal-title":"Southeast Asian J. Trop. Med. Public Health"},{"key":"10.1016\/j.ejmech.2016.11.025_bib169","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature12782","article-title":"Targeting plasmodium phosphatidylinositol 4-kinase to eliminate malaria","volume":"504","author":"McNamara","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2016.11.025_bib170","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.chom.2015.04.003","article-title":"The toxoplasma dense granule proteins GRA17 and.GRA23 mediate the movement of small molecules between the host and the parasitophorous vacuole","volume":"17","author":"Gold","year":"2015","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ejmech.2016.11.025_bib171","doi-asserted-by":"crossref","first-page":"16823","DOI":"10.1073\/pnas.1204556109","article-title":"Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target","volume":"109","author":"Yuthavong","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2016.11.025_bib172","doi-asserted-by":"crossref","first-page":"944","DOI":"10.2741\/4155","article-title":"The shikimate pathway in apicomplexan parasites: implications for drug development","volume":"18","author":"Derrer","year":"2013","journal-title":"Front. Biosci."},{"key":"10.1016\/j.ejmech.2016.11.025_bib173","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/PL00008549","article-title":"Antimalarial activity of new gossypol derivatives","volume":"86","author":"Razakantoanina","year":"2000","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.ejmech.2016.11.025_bib174","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/451065","article-title":"Exploiting unique structural and functional properties of malarial glycolytic enzymes for antimalarial drug development","author":"Alam","year":"2014","journal-title":"Malar. Res. Treat."},{"key":"10.1016\/j.ejmech.2016.11.025_bib175","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S2221-1691(11)60034-8","article-title":"Malaria parasite carbonic anhydrase: inhibition of aromatic\/heterocyclic sulfonamides and its therapeutic potential","volume":"1","author":"Krungkrai","year":"2011","journal-title":"Asian Pac. J. Trop. Biomed."},{"key":"10.1016\/j.ejmech.2016.11.025_bib176","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1042\/bj3460545","article-title":"Plasmodium falciparum-infected red blood cells depend on a functional glutathione de novo synthesis attributable to an enhanced loss of glutathione","volume":"346","author":"Luersen","year":"2000","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2016.11.025_bib177","doi-asserted-by":"crossref","first-page":"11459","DOI":"10.3390\/molecules200611459","article-title":"Plasmodium falciparum thioredoxin reductase (pftrxr) and its role as a target for new antimalarial discovery","volume":"20","author":"McCarty","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2016.11.025_bib178","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1586\/ecp.09.28","article-title":"Novel antimalarial drug targets: hope for new antimalarial drugs","volume":"2","author":"Alam","year":"2009","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2016.11.025_bib179","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1110\/ps.051891106","article-title":"Plasmodium falciparum glutathione S-transferase\u2014structural and mechanistic studies on ligand binding and enzyme inhibition","volume":"15","author":"Hiller","year":"2006","journal-title":"Prot. Sci."},{"key":"10.1016\/j.ejmech.2016.11.025_bib180","doi-asserted-by":"crossref","first-page":"e1625","DOI":"10.1371\/journal.pntd.0001625","article-title":"Selective inhibitors of protozoan protein N-myristoyltransferases as starting points for tropical disease medicinal chemistry programs","volume":"6","author":"Bell","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.ejmech.2016.11.025_bib181","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1017\/S0031182013000450","article-title":"N-Myristoyltransferase as a potential drug target in malaria and leishmaniasis","volume":"141","author":"Tate","year":"2014","journal-title":"Parasitol"},{"key":"10.1016\/j.ejmech.2016.11.025_bib182","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.bmcl.2009.02.042","article-title":"Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones","volume":"19","author":"Geyer","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.11.025_bib183","first-page":"40","article-title":"In\u00a0vitro antiplasmodial and cyclin- dependent protein kinase (pfmrk) inhibitory activities of selected flavonoids in combination with chloroquine (CQ) and artemisinin","volume":"2","author":"Akala","year":"2010","journal-title":"Res. Pharm. Biotech."},{"key":"10.1016\/j.ejmech.2016.11.025_bib184","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.2174\/156802611796575911","article-title":"6-oxopurine phosphoribosyltransferase: a target for the development of antimalarial drugs","volume":"11","author":"de Jersey","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib185","doi-asserted-by":"crossref","first-page":"6872","DOI":"10.1021\/ja0708363","article-title":"Synthesis of 5\u2032-methylthio coformycins: specific inhibitors for malarial adenosine deaminase","volume":"129","author":"Tyler","year":"2007","journal-title":"J.\u00a0Amer. Chem. Soc."},{"key":"10.1016\/j.ejmech.2016.11.025_bib186","doi-asserted-by":"crossref","first-page":"35899","DOI":"10.1074\/jbc.M807218200","article-title":"Plasmodium falciparum purine nucleoside phosphorylase is critical for viability of malaria parasites","volume":"283","author":"Madrid","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib187","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.molbiopara.2010.08.005","article-title":"Identification of inhibitors for putative malaria drug targets amongst novel antimalarial compounds","volume":"175","author":"Crowther","year":"2011","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.ejmech.2016.11.025_bib188","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.2174\/156802611796575948","article-title":"Purine and pyrimidine pathways as targets in plasmodium falciparum","volume":"11","author":"Cassera","year":"2011","journal-title":"Cur. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib189","doi-asserted-by":"crossref","first-page":"7911","DOI":"10.1021\/jm400938g","article-title":"Novel selective and potent inhibitors of malaria parasite dihydroorotate dehydrogenase: discovery and optimization of dihydrothiophenone derivatives","volume":"56","author":"Xu","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib190","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa6645","article-title":"A\u00a0long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria","volume":"7","author":"Phillips","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2016.11.025_bib191","doi-asserted-by":"crossref","first-page":"34746","DOI":"10.1074\/jbc.M113.521955","article-title":"Transition state analogues of plasmodium falciparum and human orotate phosphoribosyltransferases","volume":"288","author":"Zhang","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib192","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1021\/bi301650d","article-title":"Catalysis by orotidine 5\u2032-monophosphate decarboxylase: effect of 5-fluoro and 4\u2032-substituents on the decarboxylation of two-part substrates","volume":"52","author":"Goryanova","year":"2013","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2016.11.025_bib193","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/cmdc.201100255","article-title":"Design, synthesis, and evaluation of 5\u2032-diphenyl nucleoside analogues as inhibitors of the plasmodium falciparum dUTPase","volume":"6","author":"Hampton","year":"2011","journal-title":"Chem. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib194","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/0929867013373840","article-title":"Heme Aggregation inhibitors: antimalarial drugs targeting an essential biomineralization process","volume":"8","author":"Ziegler","year":"2001","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib195","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.2174\/092986711795328328","article-title":"Falcipains, Plasmodium falciparum cysteine proteases as key drug targets against malaria","volume":"18","author":"Teixeira","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib196","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ejmech.2015.03.049","article-title":"New paradigm of an old target: an update on structural biology and current progress in drug design towards plasmepsin II","volume":"95","author":"Dan","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib197","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3998\/ark.5550190.0013.424","article-title":"Anti-malaria drug development targeting the M1 alanyl and M17 leucyl aminopeptidases","volume":"4","author":"Thivierge","year":"2012","journal-title":"ARKIVOC"},{"key":"10.1016\/j.ejmech.2016.11.025_bib198","first-page":"704","article-title":"Artemisinin-based combination with curcumin adds a new dimension to malaria therapy","volume":"102","author":"Padmanaban","year":"2012","journal-title":"Curr. Sci."},{"key":"10.1016\/j.ejmech.2016.11.025_bib199","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.parint.2014.09.011","article-title":"Direct evidence for the atovaquone action on the Plasmodium cytochrome bc1 complex","volume":"64","author":"Siregar","year":"2015","journal-title":"Parasitol. Int."},{"key":"10.1016\/j.ejmech.2016.11.025_bib200","first-page":"S1","article-title":"New targets in malaria parasite chemotherapy: a review","volume":"S1","author":"Nigussie","year":"2015","journal-title":"Malar. contr. Elimination"},{"key":"10.1016\/j.ejmech.2016.11.025_bib201","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2174\/138945007779315579","article-title":"Fatty acid biosynthesis as a drug target in apicomplexan parasites","volume":"8","author":"Goodman","year":"2007","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejmech.2016.11.025_bib202","first-page":"101","article-title":"Apicoplast biosynthetic pathways as possible targets for combination therapy of malaria","volume":"3","author":"Tesfaye","year":"2015","journal-title":"J.\u00a0Pharm. Pharm."},{"key":"10.1016\/j.ejmech.2016.11.025_bib203","doi-asserted-by":"crossref","first-page":"663","DOI":"10.18388\/abp.2001_3901","article-title":"Isoprenoid biosynthesis via 1-deoxy-D-xylulose 5-phosphate\/2-Cmethyl-D-erythritol 4-phosphate (DOXP\/MEP) pathway","volume":"48","author":"Wanke","year":"2001","journal-title":"Acta biochim. pol."},{"key":"10.1016\/j.ejmech.2016.11.025_bib204","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1021\/jm5014264","article-title":"Synthesis and bioactivity of \u03b2-substituted fosmidomycin analogues targeting 1-deoxy-d-xylulose-5-phosphate reductoisomerase","volume":"58","author":"Chofor","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib205","first-page":"7","article-title":"Serine proteases of malaria parasite plasmodium falciparum: potential as antimalarial drug targets","author":"Alam","year":"2014","journal-title":"Interdiscip. Perspect. Infect. Dis."},{"key":"10.1016\/j.ejmech.2016.11.025_bib206","doi-asserted-by":"crossref","first-page":"33336","DOI":"10.1074\/jbc.M113.513234","article-title":"A\u00a0key role for Plasmodium Subtilisin-like SUB1 protease in egress of malaria parasites from host hepatocytes","volume":"288","author":"Tawk","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib207","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1111\/j.1742-4658.2011.08220.x","article-title":"Multi-targeted activity of maslinic acid as an antimalarial natural compound","volume":"278","author":"Moneriz","year":"2011","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2016.11.025_bib208","doi-asserted-by":"crossref","first-page":"400","DOI":"10.2174\/156802612799362968","article-title":"Reversed chloroquine molecules as a strategy to overcome resistance in malaria","volume":"12","author":"Peyton","year":"2012","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib209","doi-asserted-by":"crossref","first-page":"22393","DOI":"10.1074\/jbc.270.38.22393","article-title":"Verapamil reversal of chloroquine resistance in the malaria parasite plasmodium falciparum is specific for resistant parasites and independent of the weak base effect","volume":"270","author":"Martiney","year":"1995","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2016.11.025_bib210","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1590\/S0037-86822003000100002","article-title":"In\u00a0vitro evaluation of verapamil and other modulating agents in Brazilian chloroquine-resistant Plasmodium falciparum isolates","volume":"36","author":"Menezes","year":"2003","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"10.1016\/j.ejmech.2016.11.025_bib211","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1128\/AAC.45.9.2655-2657.2001","article-title":"Structural analysis of chloroquine resistance reversal by imipramine analogs","volume":"45","author":"Bhattacharjee","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2016.11.025_bib212","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1021\/ml5000228","article-title":"Chlorpheniramine analogues reverse chloroquine resistance in plasmodium falciparum by inhibiting PfCRT","volume":"5","author":"Deane","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.11.025_bib213","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1590\/S0074-02762002000700018","article-title":"In\u00a0vitro chloroquine resistance modulation study on fresh isolates of Brazilian Plasmodium falciparum: intrinsic antimalarial activity of phenothiazine drugs","volume":"97","author":"Menezes","year":"2002","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.ejmech.2016.11.025_bib214","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1475-2875-12-117","article-title":"Effective treatment with a tetrandrine\/chloroquine combination for chloroquine-resistant falciparum malaria in Aotus monkeys","volume":"12","author":"Ye","year":"2013","journal-title":"Malar. J."},{"key":"10.1016\/j.ejmech.2016.11.025_bib215","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1128\/AAC.44.9.2431-2434.2000","article-title":"Nonylphenolethoxylates as malarial chloroquine resistance reversal agents","volume":"44","author":"Crandall","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2016.11.025_bib216","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.exppara.2013.03.022","article-title":"Chemosensitization potential of P-glycoprotein inhibitors in malaria parasites","volume":"134","author":"Alcantara","year":"2013","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.ejmech.2016.11.025_bib217","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nri2902","article-title":"Experimental human challenge infections can accelerate clinical malaria vaccine development","volume":"11","author":"Sauerwein","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2016.11.025_bib218","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S0140-6736(04)17223-1","article-title":"Efficacy of the RTS, S\/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial","volume":"364","author":"Alonso","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2016.11.025_bib219","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1056\/NEJMoa1208394","article-title":"A\u00a0phase 3 trial of RTS, S\/AS01 malaria vaccine in African infants","volume":"367","author":"Rts","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2016.11.025_bib220","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/joim.12223","article-title":"The path of malaria vaccine development: challenges and perspectives","volume":"275","author":"Arama","year":"2014","journal-title":"J.\u00a0Intern. Med."},{"key":"10.1016\/j.ejmech.2016.11.025_bib221","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0140-6736(03)15267-1","article-title":"Malaria vaccine developments","volume":"363","author":"Moorthy","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2016.11.025_bib222","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1016\/j.vaccine.2009.03.014","article-title":"A\u00a0randomized controlled phase 2 trial of the blood stage AMA1-C1\/Al hydrogel malaria vaccine in children in Mali","volume":"27","author":"Sagara","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.ejmech.2016.11.025_bib223","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1128\/CVI.00082-10","article-title":"Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 Region II malaria vaccine in healthy adults living in an area where malaria is not endemic","volume":"17","author":"Sahly","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.ejmech.2016.11.025_bib224","doi-asserted-by":"crossref","first-page":"6862","DOI":"10.1016\/j.vaccine.2009.09.011","article-title":"Safety and immunogenicity of GMZ2-a MSP3-GLURP fusion protein malaria vaccine candidate","volume":"27","author":"Esen","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.ejmech.2016.11.025_bib225","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1016\/j.vaccine.2006.06.081","article-title":"Glutamate-rich protein (GLURP) induces antibodies that inhibit in\u00a0vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial","volume":"25","author":"Hermsen","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.ejmech.2016.11.025_bib226","doi-asserted-by":"crossref","first-page":"e4708","DOI":"10.1371\/journal.pone.0004708","article-title":"Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya","volume":"4","author":"Ogutu","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2016.11.025_bib227","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1086\/339342","article-title":"A\u00a0recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea","volume":"185","author":"Genton","year":"2002","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ejmech.2016.11.025_bib228","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.1128\/IAI.73.12.8017-8026.2005","article-title":"Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen","volume":"73","author":"Audran","year":"2005","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ejmech.2016.11.025_bib229","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/infdis\/jit185","article-title":"The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas","volume":"208","author":"Jepsen","year":"2013","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ejmech.2016.11.025_bib230","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.parint.2010.05.002","article-title":"Evidences of protection against blood-stage infection of Plasmodium falciparum by the novel protein vaccine SE36","volume":"59","author":"Horii","year":"2010","journal-title":"Parasitol. Int."},{"key":"10.1016\/j.ejmech.2016.11.025_bib231","doi-asserted-by":"crossref","first-page":"e64073","DOI":"10.1371\/journal.pone.0064073","article-title":"Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36","volume":"8","author":"Palacpac","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2016.11.025_bib232","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1475-2875-11-11","article-title":"A\u00a0review of malaria vaccine clinical projects based on the WHO rainbow table","volume":"11","author":"Schwartz","year":"2012","journal-title":"Malar. J."},{"key":"10.1016\/j.ejmech.2016.11.025_bib233","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1128\/IAI.73.11.7375-7380.2005","article-title":"Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum","volume":"73","author":"Arakawa","year":"2005","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ejmech.2016.11.025_bib234","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4269\/ajtmh.2005.73.32","article-title":"Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade PVS25 recombinant protein","volume":"73","author":"Arevalo-Herrera","year":"2005","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ejmech.2016.11.025_bib235","doi-asserted-by":"crossref","first-page":"6618","DOI":"10.1128\/IAI.68.12.6618-6623.2000","article-title":"Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes","volume":"68","author":"Hisaeda","year":"2000","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ejmech.2016.11.025_bib236","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1073\/pnas.0913374107","article-title":"A\u00a0bicomponent Plasmodium falciparum investigational vaccine composed of protein-peptide conjugates","volume":"107","author":"Kubler-Kielb","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2016.11.025_bib237","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1186\/1475-2875-11-372","article-title":"MALVAC 2012 scientific forum: accelerating development of second-generation malaria vaccines","volume":"11","author":"Vannice","year":"2012","journal-title":"Malar. J."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523416309631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523416309631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T15:12:16Z","timestamp":1718896336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523416309631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":237,"alternative-id":["S0223523416309631"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2016.11.025","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive review on various strategies for antimalarial drug discovery","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2016.11.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}